Midpregnancy testing for soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF): An inter-assay comparison of three automated immunoassay platforms.
Sign Up to like & getrecommendations! Published in 2019 at "Placenta"
DOI: 10.1016/j.placenta.2019.08.083
Abstract: We performed an inter-assay comparison among three immunoassay platforms for midpregnancy testing of sFlt-1, PlGF and the sFlt-1/PlGF ratio, which are established markers for pre-eclampsia. Maternal blood was collected 19-22 weeks' gestation. Raw data values… read more here.
Keywords: sflt; immunoassay platforms; inter assay; assay comparison ... See more keywords
Abstract 5146: Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5146
Abstract: Introduction: The expression of programmed cell death ligand-1 (PD-L1) is a predictive biomarker for the efficacy of pembrolizumab in advanced non-small cell lung cancer (NSCLC). While several assays have been approved for evaluating PD-L1 expression… read more here.
Keywords: pembrolizumab; assay discrepancy; discrepancy; inter assay ... See more keywords
Inter-assay variability of next-generation sequencing-based gene panels
Sign Up to like & getrecommendations! Published in 2022 at "BMC Medical Genomics"
DOI: 10.1186/s12920-022-01230-y
Abstract: Background Tumor heterogeneity has been known to cause inter-assay discordance among next-generation sequencing (NGS) results. However, whether preclinical factors such as sample type, sample quality and analytical features of gene panel can affect the concordance… read more here.
Keywords: panel; inter assay; generation sequencing; next generation ... See more keywords